These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2840373)

  • 1. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.
    Fareed J; Walenga JM; Racanelli A; Hoppensteadt D; Huan X; Messmore HL
    Haemostasis; 1988; 18 Suppl 3():33-47. PubMed ID: 2840373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of LMWHs.
    Samama MM; Gerotziafas GT
    Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
    Frydman A
    Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparins: pharmacologic profile and product differentiation.
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Am J Cardiol; 1998 Sep; 82(5B):3L-10L. PubMed ID: 9737473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacologic inequivalence of low molecular weight heparins.
    Fareed J; Walenga JM; Hoppensteadt D; Huan X; Nonn R
    Ann N Y Acad Sci; 1989; 556():333-53. PubMed ID: 2544128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?
    Andrassy K; Eschenfelder V
    Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
    Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M
    Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human pharmacokinetics of low molecular weight heparins.
    Cornelli U; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and low molecular weight heparin: background and pharmacology.
    Morris TA
    Clin Chest Med; 2003 Mar; 24(1):39-47. PubMed ID: 12685055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates.
    Kouta A; Jeske W; Cera L; Farshid A; Duff R; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2021; 27():10760296211005544. PubMed ID: 33926250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.